The hospital partnership is between the Tata Medical Centre (TMC) in Calcutta, India and the Paediatric Oncology and Haematology Research Department at the Charité Berlin. The hospital partners are working together to introduce new standard procedures in detecting minimal residual disease following cancer treatment.
Context:
Families in India with children suffering from leukaemia have to pay for treatment themselves. Without a risk assessment, all children with leukaemia have to undergo intensive cancer treatment. This increases both the mortality rate and the costs of treatment. The methodology for detecting minimal residual disease in patients with leukaemia, which the Charité was involved in developing, makes it possible to select appropriate cancer treatment.
Activities:
-\tTwo-monthly virtual meetings of the project partners
-\tUpgrading data analysis and risk management skills
-\tImplementing the diagnostic gold standard in detecting residual cancer at TMC.
Result:
The clinic partners improve their ability to detect minimal residual disease in patients with leukaemia. This results in better health outcomes following cancer treatment. Furthermore, the costs of individual treatment are lower.